Memantine And Donepezil Hydrochlorides Extended-release Capsule, Extended Release
Product Images NDC 69238-1248

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Memantine And Donepezil Hydrochlorides Extended-release (NDC 69238-1248). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Ny Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem Structure 1 (Memantine And Donepezil Hydrochlorides Extended Re 1)

Chemical structure of Memantine, represented as a three-dimensional ring structure with an amino group (NH2) and hydrochloride (HCl) group, corresponding to the active ingredient in Memantine and Donepezil Hydrochlorides Extended-release capsules.*

FDA Label Image

Figure 8 (Memantine And Donepezil Hydrochlorides Extended Re 10)

A cumulative percentage of patients chart comparing donepezil hydrochloride 10 mg/day and placebo groups, showing the ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) change from baseline on the x-axis and cumulative patient percentages on the y-axis. The data illustrate the distribution of patient responses for both treatment and placebo over a range of ADCS-ADL score changes.*

FDA Label Image

14mg Label (Memantine And Donepezil Hydrochlorides Extended Re 11)

Label for Memantine and Donepezil Hydrochlorides Extended-release Capsules 7 mg/10 mg by Amneal Pharmaceuticals LLC. The label indicates the capsule strength is 7 mg memantine HCl and 10 mg donepezil HCl, with a quantity of 90 capsules. Instructions mention storing between 20° to 25°C and dispensing in a light-resistant container. The label includes the NDC 69238-1552-9 and a barcode.*

FDA Label Image

28mg Label (Memantine And Donepezil Hydrochlorides Extended Re 12)

Label for Memantine and Donepezil Hydrochlorides Extended-release Capsules, 14 mg/10 mg strength. The label includes the product name, dosage form as extended-release capsules, and a capsule image marked with 'AN 1248'. It states 'Rx only' and a quantity of 90 capsules. Distributed by Amneal Pharmaceuticals, Bridgewater, NJ. The label also presents storage instructions and a barcode.*

FDA Label Image

Memantine And Donepezil Hydrochlorides Extended Re 13

Label for Memantine and Donepezil Hydrochlorides Extended-release Capsules, strength 21 mg/10 mg. The label indicates 90 capsules in the package and shows a yellow capsule imprinted with "AN" and "1553". The labeler is Amneal Pharmaceuticals LLC, Bridgewater, NJ. Storage and usage instructions are also present.*

FDA Label Image

Memantine And Donepezil Hydrochlorides Extended Re 14

Memantine and Donepezil Hydrochlorides Extended-release Capsules 28 mg/10 mg label from Amneal Pharmaceuticals NY LLC. The label includes an image of a yellow capsule with imprint 'AN 1247,' and states the package contains 90 capsules. It lists each capsule contains 28 mg memantine HCl extended-release and 10 mg donepezil HCl. Storage and dosage instructions are also visible along with a barcode and distributor information.*

FDA Label Image

Chem Structure 2 (Memantine And Donepezil Hydrochlorides Extended Re 2)

Chemical structure of Memantine and Donepezil Hydrochlorides Extended-release active ingredient, showing a molecular diagram with aromatic rings, oxygen, and nitrogen atoms along with hydrochloride (HCl) notation.*

FDA Label Image

Figure 1 (Memantine And Donepezil Hydrochlorides Extended Re 3)

A line graph showing mean change from baseline in SIB score over 24 weeks of treatment. It compares Memantine HCl ER 28 mg/AChEI with Placebo/AChEI, illustrating clinical improvement and decline trends, with error bars indicating variability in data points.*

FDA Label Image

Figure 2 (Memantine And Donepezil Hydrochlorides Extended Re 4)

A cumulative percentage curve graph showing the change from baseline in SIB (Severe Impairment Battery) scores. The graph compares Memantine HCl ER 28 mg/ACHE treatment versus placebo/ACHE, depicting SIB improvement trends over a range of baseline changes in patients.*

FDA Label Image

Figure 3 (Memantine And Donepezil Hydrochlorides Extended Re 5)

A line graph comparing treatment effects over 24 weeks, showing mean change in CDR-Sum of Boxes scores for Memantine HCl ER 28 mg/AChE inhibitor versus placebo/AChE inhibitor. The y-axis represents the mean score with clinical improvement and decline labeled, and the x-axis shows weeks of treatment.*

FDA Label Image

Figure 4 (Memantine And Donepezil Hydrochlorides Extended Re 6)

A bar graph comparing the percentage of patients with varying levels of change according to the CIBIC-Plus Rating for Memantine Hydrochloride Extended-Release 28 mg plus AChEI versus Placebo plus AChEI. Categories include marked improvement, moderate improvement, minimal improvement, no change, minimal worsening, moderate worsening, and marked worsening.*

FDA Label Image

Figure 5 (Memantine And Donepezil Hydrochlorides Extended Re 7)

A line graph showing the change in SIB (Severe Impairment Battery) score from baseline over 6 months of treatment. It compares donepezil hydrochloride 10 mg/day versus placebo. The y-axis indicates change from baseline (mean ± SE), highlighting clinical improvement above baseline and clinical decline below it. The donepezil group shows improvement, whereas the placebo group shows decline over time.*

FDA Label Image

Figure 6 (Memantine And Donepezil Hydrochlorides Extended Re 8)

A cumulative percentage graph showing patient response for donepezil hydrochloride 10 mg/day versus placebo. The x-axis represents SIB change from baseline, ranging from positive to negative values, and the y-axis represents the cumulative percentage of patients from 0% to 100%. The donepezil group (solid circles) shows a higher cumulative response compared to placebo (open squares). A vertical dashed line marks the zero SIB change from baseline.*

FDA Label Image

Figure 7 (Memantine And Donepezil Hydrochlorides Extended Re 9)

A line graph comparing the change from baseline in ADCS-ADL scores over six months of drug treatment for donepezil hydrochloride 10 mg/day versus placebo. The y-axis shows mean change from baseline, with indicators for clinical improvement and decline, and the x-axis shows months of treatment. Data points with error bars illustrate a less pronounced decline for the donepezil group compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.